NCT04975893View on ClinicalTrials.gov

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

291

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Cytomegalovirus Infection
Interventions
BIOLOGICAL

mRNA-1647

No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.

OTHER

mRNA-1647

Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration

Trial Locations (7)

40509

Alliance for Multispeciality Research, LLC, Lexington

61610

Optimal Research, LLC, Peoria

66219

Johnson County Clin-Trials, Inc., Lenexa

77901

Crossroads Clinical Research (Victoria), Victoria

78745

Tekton Research Inc, Austin

84109

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

84121

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY